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The added effect of thioridazine in the 
treatment of drug-resistant tuberculosis 
The review by Grosset et al. in a recent issue of the 
Journal is highly interesting, and rightly pictures a 
bright horizon for the improved treatment of tuber-
culosis.1 However, there are alternative compounds 
that can already provide considerable relief in com-
passionate application of treatment for multidrug-
r esistant and extensively drug-resistant tuberculosis 
(MDR/XDR-TB) in the short term, and may offer an 
important additional effect in treatment regimens due 
to a special working mechanism, such as effl ux pump 
inhibition. The review did not, for example, discuss 
the successful use of the neuroleptic thioridazine (TZ) 
in MDR/XDR-TB treatment, although it has been 
widely examined and published. Our correspondence 
therefore addresses this omission and summarises in 
vitro, ex vivo and mouse studies of TZ, as well as the 
use of TZ in treatment of TB patients as monotherapy 
or as an adjunct in combination with drugs to which 
the causative Mycobacterium tuberculosis was initially 
resistant.
It has been known for many years that pheno-
thiazines, and especially the traditional neuroleptic 
chlorpromazine (CPZ), possess in vitro activity against 
M. tuberculosis.2 However, because the mode of ac-
tion occurs at concentrations that are not consid-
ered tolerable in humans,2 interest in CPZ as an anti-
tuberculosis agent did not develop. Moreover, although 
these have been highly infrequent, the compound has 
been associated with serious side effects.3 Nonethe-
less, with the emergence of MDR-TB in the late 
1980s, CPZ regained interest as an anti-tuberculosis 
agent. In New York, new TB cases quadrupled during 
this period, more than half of these caused by MDR 
strains.4 This re-emphasised the need for alternative 
treatments for TB, and at the time it was demonstrated 
that CPZ enhanced the killing of newly phagocytosed 
M. tuberculosis in human macrophages at clinically 
tolerable concentrations.5 This observation regener-
ated interest in phenothiazines. Soon after, the milder 
phenothiazine, TZ, also showed considerable in vitro 
activity against all tested MDR-TB isolates.6,7 Al-
though the concentrations needed to inhibit the in 
vitro replication of MDR-TB isolates were still too 
high for clinical application, concentrations that en-
hanced the killing of newly phagocytosed MDR-TB 
bacteria were considered clinically tolerable,8 reveal-
ing an important added effect of this class of drugs. 
After in vitro studies, animal models are the next 
step in research on the effi cacy of drugs. TZ appeared 
highly effective as a sole drug in the treatment of both 
susceptible9 and MDR-TB in the Balb/C mouse model, 
and showed an added effect in combination with other 
drugs.10 In the coming period, TZ and other drugs 
with a similar working mechanism, such as SILA421,11 
could be tested for their added value in treatment of 
TB in combination with the promising new drugs 
TMC207, PA824, PNU100480 or SQ109. In addition, 
higher dosages of rifampicin (RMP) are currently 
being tested in a drug trial in Tanzania and South 
A frica, and the utility of phenothiazines or similar 
drugs to acquire higher intracellular RMP concentra-
tions at even lower dosage is worth exploring. 
The recent report on totally drug-resistant tuber-
culosis (TDR-TB) from Mumbai exemplifi es the ur-
gent need for alternative treatments for TB; in the 
short term TZ may therefore be more important than 
realised.12 Patients diagnosed with TDR-TB have al-
ready been exposed to virtually all available fi rst- and 
second-line drugs without a favourable response, and 
physicians have run out of regular options. New TB 
drugs are therefore desperately needed to treat this 
category of patients. However, until the new drugs 
become available we will have to work with all drugs 
currently at hand. 
Given the above, we fi rst tested the safety and effi -
cacy of TZ as salvage treatment in four Indian pa-
tients confronted with XDR (nearly totally) TB. We 
found it well tolerated and safe, even in malnour-
ished patients who had failed treatment with all other 
drugs,13 and we documented clinical and radiological 
improvement in three of the four patients.13 In this 
small series, TZ was applied out of compassionate 
use, and treatment was started too late to achieve full 
bacteriological cure. Larger trials with TZ added on 
to standardised or individualised XDR-TB regimens 
at an earlier stage are foreseen. TZ has also been 
added to the salvage treatment regimens of three of 
the 15 cases of TDR-TB described by the Hinduja 
Hospital in Mumbai; these patients are also showing 
clinical, radiological and in two cases even a micro-
biological response. 
Current drug choices for treating XDR- or TDR-
TB are scarce. Information on the safety, tolerability 
and effi cacy of alternative regimens is therefore of 
utmost importance. A retrospective study was per-
formed among 17 adult pulmonary XDR-TB patients 
without the acquired immune-defi ciency syndrome 
admitted to a referral treatment centre for infectious 
diseases in Buenos Aires, Argentina, from 2002 to 
2008.14 Drug combination schemes to treat these pa-
tients were tailored on the basis of drug susceptibility 
testing and the patient’s drug tolerance. A combina-
tion of linezolid, moxifl oxacin and TZ was applied in 
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the treatment of 12 of the patients. TZ was initially 
administered at a daily dose of 25 mg for 2 weeks, 
after which the dose was increased to 25 mg weekly 
until it reached 200 mg /day, under strict cardiac moni-
toring for eventual cardiac adverse events. Eleven pa-
tients met the recovery criteria with more than 2 years 
of follow-up after treatment completion. TZ was 
discontinued in one patient with pancytopaenia and 
in another with allergic dermatitis. Although cardiac 
adverse effects have been reported previously, no 
prolongation of QT interval or any other heart com-
plication was observed.
The activity of TZ against the drug-resistant strain 
of M. tuberculosis that resides in the pulmonary mac-
rophage of the alveoli is assumed to occur via two 
distinct mechanisms.15 First, it enhances the killing of 
M. tuberculosis within the phagolysosome by inhibit-
ing the cellular effl ux of potassium, thereby promoting 
the acidifi cation of the vacuole and activation of its 
hydrolases.16 Second, because TZ inhibits the effl ux 
pumps of mycobacteria, which are partially respon-
sible for their resistance phenotype,1 antibiotics that 
would normally be extruded by these effl ux pumps 
because the intended target concentration cannot be 
reached are retained due to the inhibition of the ef-
fl ux pumps by TZ.2,17 Whereas the fi rst mechanism 
avoids selection of mutated bacteria, the second mech-
anism ensures the effectiveness of the drugs when TZ 
increases the intra-cellular drug concentrations.
Treatment of TB is increasingly hampered by the 
emergence of anti-tuberculosis drug resistance. The 
rate of resistance is high not only in retreatment cases, 
but also in new, previously untreated cases.18 This 
indicates transmission of resistant M. tuberculosis 
strains with presumably a higher level of intrinsic 
resistance to withstand exposure to drugs. The genet-
ically conserved Beijing genotype strains have fre-
quently been associated with drug resistance in the 
countries of the former Soviet Union and Asia. It was 
recently shown that some of these strains have ele-
vated rates of RMP-r esistant mutants,19 and this may 
be a highly conceivable explanation for some of the 
resistance problems currently faced in these regions. 
However, in Europe also, the Beijing genotype in par-
ticular is associated with transmission of MDR/XDR-
TB.19 To combat the emergence of resistant TB, new 
drugs are in the pipeline. However, existing drugs, 
improved treatment regimens and more effi cient dos-
ages should also be explored in the short term to pre-
vent morbidity and mortality. In particular, the syner-
gistic effects of drug combinations have not been 
addressed suffi ciently. TZ may have an added effect 
on the effi cacy of all drugs due to its specifi c mode of 
activity, which yields higher intra-cellular concentra-
tions of drug.
In conclusion, at the time of writing, only TZ has 
proven effective in the therapy of XDR-TB.14 The ad-
junct use of TZ in combination with antibiotics to 
which the infecting organism was initially resistant is 
highly promising, and is recommendable out of com-
passionate consideration. In such cases, appropriate 
measures should be taken to limit or prevent any 
cardiopathy associated with TZ treatment, although 
the drug is generally safe to use.13,14 In the USA, un-
successful treatment of a single MDR-TB case can 
cost as much as $500 000,20 whereas for a few hun-
dred dollars an XDR-TB patient can be successfully 
treated with TZ. This drug should be considered in 
low-income regions of the world where the preva-
lence of MDR/XDR-TB is high. Moreover, because of 
its dual mechanism of action, TZ is expected to result 
in similar cure rates in TDR-TB patients.21 A more 
scientifi c approach, with greater numbers of patients, 
should determine the true effi cacy of TZ and similar 
drugs. This should not withhold the application of 
these drugs in compassionate use today.
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In reply
We are grateful to Drs Amaral et al. for their nice 
comments about our review on the new drugs for the 
treatment of tuberculosis (TB), and are pleased to re-
spond to their comments about not having included 
thioridazine among the new drugs for TB. Let us re-
member that the objective of our review was ‘to 
r eport evidence about the effi cacy and potential of 
currently licensed drugs and new molecules beyond 
pre-clinical development for improving the chemo-
therapy of tuberculosis’. Thioridazine, an antipsychotic 
drug, is a piperidine belonging to the phenothiazine 
drug group. It replaced the fi rst successful neuroleptic 
chlorpromazine (Largactil®), and was previously widely 
used in the treatment of schizophrenia and psychosis.1 
Its usual dosage was 50 mg per day for mild cases to 
600–800 mg /day for severely disturbed patients. It was 
associated with cardiac and neuro-psychiatric side 
e ffects. The manufacturer Novartis/Sandoz/Wander 
of the thioridazine brands, Mellaril in the USA and 
Canada and Melleril in Europe, discontinued the drug 
worldwide in June 2005. Thioridazine may still be 
available from other manufacturers as a generic drug, 
with the precaution that it be used only in psychotic 
patients who are refractory to other forms of drug 
treatment. 
The activity of the phenothiazines against Myco-
bacterium tuberculosis is fairly controversial. The 
minimum inhibitory concentration (MIC) of chlor-
promazine for M. tuberculosis is 15–25 μg/ml, well 
above the maximum plasma concentration achieved 
in chronically treated humans, i.e., 0.5 μg/ml. Thio-
ridazine has a similar MIC to that of chlorproma-
zine but, like chlorpromazine, is concentrated inside 
macrophages, and was demonstrated to have activity 
against M. tuberculosis in cell culture.2 In the mouse 
infected with drug-susceptible M. tuberculosis, treat-
ment for 32 and 70 days with thioridazine alone at 
daily doses of 32 and 70 mg/kg reduced the colony-
forming unit (cfu) counts in lungs by 0.2–0.4 log10 
compared with untreated controls. In the mouse in-
fected with MDR M. tuberculosis, treatment with 
thioridazine alone at daily doses of 32 and 70 mg /kg 
reduced the cfu counts by 0.1–0.2 log10.3 Anecdotal 
successes have been reported in humans with MDR-
TB having received thioridazine-containing treatment 
on a compassionate basis.1 
For all of these reasons, we did not, and we still do 
not think that thioridazine had to be included among 
drugs beyond pre-clinical development for improving 
the chemotherapy of tuberculosis. 
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